News | April 12, 2026
EMA gives green light to warmer & simpler delivery rules for Wegovy injection
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
These surgeries involve no bone cuts, minimal surgical trauma, smaller incisions and significantly reduced blood loss
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
The company says the platform offers improved manufacturability and functional advantages
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The event also featured discussions on emerging trends in joint replacement surgery
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
The approval clears the way for a US study at leading clinical centers to evaluate the safety and effectiveness of VDYNE’s system in patients
Subscribe To Our Newsletter & Stay Updated
